Page 147 - MEMORIA ANUAL 2020

MEMORIA ANUAL 2020
SOCIEDAD ESPAÑOLA FUNDACIÓN ESPAÑOLA
DE HEMATOLOGÍA Y HEMOTERAPIA DE HEMATOLOGÍA Y HEMOTERAPIA
• Chronic myeloid leukemia prognosis and therapy: criticisms and perspectives. J Clin Med. 2020 Jun 2;9(6):1709. doi: 10.3390/jcm9061709. PMID: 32498406.
Russo D, García-Gutiérrez JV, Soverini S, Baccarani M.
• Bosutinib for pretreated patients with chronic phase chronic myeloid leukemia: primary results of the phase 4 BYOND study.
Leukemia. 2020 Aug;34(8):2125-2137. doi: 10.1038/s41375-020-0915-9. Epub 2020 Jun 22. PMID: 32572189.
Hochhaus A, Gambacorti-Passerini C, Abboud C, Gjertsen BT, Brümmendorf TH, Smith BD, Ernst T, Giraldo-Castellano P, Olsson-Strömberg U, Saussele S, Bardy-Bouxin N, Viqueira A, Leip E, Russell- Smith TA, Leone J, Rosti G, Watts J, Giles FJ; BYOND Study Investigators.
• Cutaneous side effects in a cohort of patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: general description and further characterization, correlation with photoexposition and study of hypopigmentation as treatment’s prognostic factor.
Dermatol Ther. 2020 Nov;33(6):e14428. doi: 10.1111/dth.14428. Epub 2020 Nov 3. PMID: 33073453.
Llamas-Velasco M, Ovejero-Merino E, García-Diez A, Requena L, Daudén E, Steegmann JL.
• Identification of immunological parameters as predictive biomarkers of relapse in patients with chronic myeloid leukemia on treatment-free remission.
J Clin Med. 2020 Dec 25;10(1):42. doi: 10.3390/jcm10010042. PMID: 33375572.
Vigón L, Luna A, Galán M, Rodríguez-Mora S, Fuertes D, Mateos E, Piris-Villaespesa M, Bautista G, San José E, Rivera-Torres J, Steegmann JL, de Ory F, Pérez-Olmeda M, Alcamí J, Planelles V, López-Huertas MR, García-Gutiérrez V, Coiras M.
• Predictive indicators of successful tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia.
World J Clin Oncol. 2020 Dec 24;11(12):996-1007. doi: 10.5306/wjco.v11.i12.996. PMID: 33437662.
Stuckey R, López-Rodríguez JF, Sánchez-Sosa S, Segura-Díaz A, Sánchez-Farías N, Bilbao-Sieyro C, Gómez-Casares MT.
GRUPO ESPAÑOL DE LEUCEMIA MIELOIDE CRÓNICA (GELMC)
147